Theravance Biopharma Rating Lowered to Underperform at Robert W. Baird (TBPH)
Theravance Biopharma (NASDAQ:TBPH) was downgraded by equities researchers at Robert W. Baird from a “neutral” rating to an “underperform” rating in a research report issued on Thursday, TheFlyOnTheWall.com reports. They currently have a $21.00 price objective on the stock. Robert W. Baird’s price target indicates a potential downside of 29.17% from the company’s current price.
Theravance Biopharma (NASDAQ:TBPH) traded down 6.90% on Thursday, hitting $27.605. 39,340 shares of the company’s stock traded hands. Theravance Biopharma has a one year low of $14.75 and a one year high of $35.675. The stock’s 50-day moving average is $31.29 and its 200-day moving average is $29.0. The company’s market cap is $890.5 million.
Theravance Biopharma (NASDAQ:TBPH) last posted its quarterly earnings results on Thursday, August 14th. The company reported ($1.83) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.56) by $1.27.
Separately, analysts at Bank of America initiated coverage on shares of Theravance Biopharma in a research note on Friday, June 6th. They set a “buy” rating and a $34.00 price target on the stock.
Theravance Biopharma, Inc, is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of small molecule medicines across a number of therapeutic areas including bacterial infections, central nervous system (NASDAQ:TBPH)/pain, respiratory disease, and gastrointestinal (GI) motility dysfunction.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.